Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDORA Effect? For Accelerated Approval Class Of 2023, Most Confirmatory Trials At Least Underway

30 Jan 2024

• By Sue Sutter

alarm clock — Sponsors are getting an earlier start on planning for confirmatory trials. • Source: Shutterstock

Related Content

US FDA Has History Of Pushing Sponsors On Confirmatory Trials … Sometimes

26 Jan 2023

FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials

24 Sep 2023

Slim Adcomm Majority Boosts Sarepta’s Gene Therapy In Duchenne Muscular Dystrophy

13 May 2023

Accelerated Approval: US FDA Should Explain Why An Ongoing Trial Is Not Required

02 Feb 2023

Confirmatory Studies For Rare Diseases Shouldn’t Need To Start Before Accelerated Approval, Stakeholders Argue

27 Jun 2023

Accelerated Approval Drugs’ Fate Rests Heavily On Current Therapeutic Landscape When Confirmatory Trials Are Overdue

28 Nov 2023

Accelerated Approval: US FDA Writing Guidance On What ‘Ongoing’ Means For Confirmatory Trials

15 Nov 2023

Confirmatory Trials: Comprehensive Development Plan, Early Communication Will Help Reduce Delays, US FDA Says

21 Nov 2023

Elevidys And The EMBARK Trial: Is Another Advisory Committee Meeting Coming?

01 Nov 2023

Eisai/Biogen’s Leqembi: US FDA’s Full Approval Comes With A Boxed Warning On ARIA Risk

07 Jul 2023

Pazdur On Accelerated Approval: FDA Needs To Explain Why It Does Not Always Seek Withdrawal When Trials Fail

30 Jan 2024

Accelerated Approval Withdrawals: Will Non-Oncology Indications Stop ‘Dangling’ In 2024?

30 Jan 2024

Confirmatory Trials: Flexibility In Timing Hinges On Accelerated Approval Indication Size – FDA’s Marks

30 Jan 2024

Accelerated Approval Reforms Give US FDA More Power And Flexibility – With Some Gaps

21 Dec 2022

Accelerated Approval: US FDA Wants Comprehensive Development Plan From Oncology Sponsors

22 Sep 2021

Related Companies

Acrotech Biopharma LLC

Eisai Co., Ltd.

Biogen, Inc.

Sarepta Therapeutics, Inc.

Valneva SE

Additional Topics

United States Review Pathway Drug Approval Standards Approvals Post Market Regulation & Studies Regulation Pink Sheet Perspectives BioPharmaceutical

More from Pink Sheet Perspectives

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.